Showing results (221-230 of 314) with videos related to

Sort By:
Pageof 32
Journal for Immunotherapy of Cancer|January 2, 2023
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancerVincenzo Nasca, Francesco Barretta, Francesca Corti, et al.
Molecular Cancer Therapeutics|October 5, 2013
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutationsPrasanth Ganesan, Filip Janku, Aung Naing, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2020
JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusionsT Yoshino, G Pentheroudakis, S Mishima, et al.
Annals of Surgical Oncology|October 23, 2023
Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable BenefitNeal Bhutiani, Travis E Grotz, Seth J Concors, et al.
Oncotarget|August 20, 2016
Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentinMichael J Overman, Van Morris, Helen Moinova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2021
Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown PrimaryKanwal Raghav, Hyunsoo Hwang, Alexandre A Jácome, et al.
Journal for Immunotherapy of Cancer|January 4, 2025
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitorsJulien Taieb, Margherita Ambrosini, Emily Alouani, et al.
Journal of Hematology & Oncology|July 3, 2026
KRAS inhibition is an effective therapy for appendiceal adenocarcinomaSaikat Chowdhury, Ichiaki Ito, Vinay K Pattalachinti, et al.
JAMA Network Open|May 17, 2023
Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical TrialsMarcus A Florez, Joseph Abi Jaoude, Roshal R Patel, et al.
The Oncologist|April 14, 2026
Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancerVincenzo Nasca, Margherita Ambrosini, Julien Taieb, et al.
Pageof 32